749 related articles for article (PubMed ID: 35081305)
21. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
22. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
23. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
24. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
25. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
[TBL] [Abstract][Full Text] [Related]
27. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
[TBL] [Abstract][Full Text] [Related]
28. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
29. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
Drugs Context; 2020; 9():. PubMed ID: 33240390
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
31. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.
Zhang Y; Jiang G
Front Immunol; 2024; 15():1341632. PubMed ID: 38444845
[TBL] [Abstract][Full Text] [Related]
32. Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication.
Murphrey M; Waldman RA; Durso T; Grant-Kels JM
J Am Acad Dermatol; 2022 Jan; 86(1):42-43. PubMed ID: 34600033
[No Abstract] [Full Text] [Related]
33. Janus kinase inhibitors in dermatology: A systematic review.
Shreberk-Hassidim R; Ramot Y; Zlotogorski A
J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
[TBL] [Abstract][Full Text] [Related]
34. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F; Meier K; Ghoreschi K
Front Immunol; 2019; 10():2847. PubMed ID: 31849996
[TBL] [Abstract][Full Text] [Related]
35. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders.
Corbella-Bagot L; Riquelme-McLoughlin C; Morgado-Carrasco D
Actas Dermosifiliogr; 2023 Oct; 114(9):784-801. PubMed ID: 37331618
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase inhibitors for the therapy of atopic dermatitis.
Traidl S; Freimooser S; Werfel T
Allergol Select; 2021; 5():293-304. PubMed ID: 34532638
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders.
Corbella-Bagot L; Riquelme-McLoughlin C; Morgado-Carrasco D
Actas Dermosifiliogr; 2023 Oct; 114(9):T784-T801. PubMed ID: 37543140
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
40. Comparing available JAK inhibitors for treating patients with psoriasis.
Funk PJ; Perche PO; Singh R; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):281-294. PubMed ID: 35129030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]